Development of a Surface Programmable Activation Receptor system (SPAR): A living cell biosensor for rapid pathogen detection
Kittle, J. D.; Lwande, J. S.; Williams, M. R.; Brody, R.; Frenchmeyer, M.; Hua, J.; Liang, S.; McQuaide, K.; Mo, M.; Neese, A.; Tang, Y.; Vedamoorthy, S.; Zeng, L.; Zupancic, T.; McBrairty, C.
Show abstract
Efficient pathogen detection is essential for the successful treatment and prevention of infectious disease; however, current methods are often too time intensive to be clinically relevant in cases requiring immediate intervention. We have developed a Surface Programmable Activation Receptor (SPAR) diagnostic platform comprised of universal biosensor cells engineered for use in combination with custom or commercial antibodies to achieve rapid and sensitive pathogen detection. SPAR cells are stably transfected Jurkat T cells designed to constitutively express a modified T cell mouse Fc{gamma}RI receptor on the cell surface and a high level of the luminescent reporter protein aequorin in the cytoplasm. The modified mFc{gamma}RI-CD3{zeta} receptor protein binds with high affinity to the Fc region of any full-length mouse IgG2a and some IgG2 antibodies: this allows customized target detection via the selection of specific antibodies. T-cell receptor aggregation in response to target antigen binding results in signal transduction which, when amplified via the endogenous T cell signal cascade, triggers the rapid intracellular release of calcium. Increased Ca2+ concentrations activate the expressed reporter protein aequorin resulting in the immediate emission of detectable light. Testing demonstrates the accurate and specific detection of numerous targets including P. aeruginosa, E. coli O111, and E. coli O157. We report that the SPAR biosensor cell platform is a reliable pathogen detection method that enables the rapid identification of bacterial causative agents using standard laboratory instrumentation. The technology lends itself to the development of efficient point-of-care testing and may aid in the implementation of effective and pathogen-specific clinical therapies.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody 94%
- A High-throughput Multi-Species Platform Using Biolayer Interferometry Immunosorbent Assay (BLI-ISA) as an Alternative to Indirect ELISA for Vaccine Development 93%
- Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples 92%
Similar papers in this journal
- Selection of Human Single Domain Antibodies (sdAb) Against Thymidine Kinase 1 and Their Incorporation Into sdAb-Fc Antibody Constructs For Potential Use In Cancer Therapy 93%
- SARS-CoV2 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after infection 93%
- Functional and structural consequences of epithelial cell invasion by Bordetella pertussis adenylate cyclase toxin 92%
Similar papers in this journal
Similar papers in this journal
- A Bacterial Living Therapeutics with Engineered Protein Secretion Circuits To Eliminate Breast Cancer Cells 92%
- Robust characterization of two distinct glutarate sensing transcription factors found in Pseudomonas putida L-lysine metabolism 92%
- Construction and Functional Characterization of a Heterologous Quorum Sensing Circuit in Clostridium sporogenes 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.